Navigation Links
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Date:11/11/2013

forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com

 CONSOLIDATED STATEMENTS OF OPERATIONS (1)(U.S. dollars in thousands, except per share data)Three months endedSeptember 30,20132012Revenues$1,552$509Cost of Revenues

750230Gross Profit802279Operating Expenses:Research and development expenses

1,544946Selling and marketing

830402General and administrative

2,3132,212Total operating expenses

4,6873,560Loss from Operations

(3,885)(3,281)Financial expenses

574,218Loss before income taxes

(3,942)(7,499)Tax expenses

37Net Loss($3,945)($7,506)Net loss per share – basic and diluted

($0.12)($0.44)Weighted average number of shares of common stock used in
computing net loss per share – basic and diluted

33,959,77317,074,235 RECONCILIATION OF NON-GAAP NET LOSS (2)(U.S. dollars in thousands, except per share data)Three months endedSeptember 30,20132012GAAP Net Loss($3,945)($7,506)Non-GAAP Adjustments:Non
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
(Date:8/31/2015)... Rosa Beach, FL (PRWEB) , ... August 31, 2015 , ... ... family of companies – has teamed up with fellow South Walton property management ... focused on eliminating extreme poverty in remote parts of the world. The two companies ...
(Date:8/31/2015)... ... ... The Lisle family law firm of Momkus McCluskey, LLC is pleased ... earn a “Leading Lawyers” distinction. , The “Leading Lawyers” distinction is ... nomination process is based on statewide peer survey nominations and the approval of the ...
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... to start from and those who are interested in learning more about the procedure ... Dr. Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding ... injury has been largely untreatable - with mostly palliative treatments only - and ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical and ... orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , Dr. ...
Breaking Medicine News(10 mins):Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2
... in German . , On 7 ... in Health Care (IQWiG) published the results of a ... heart disease (CHD). The aim of the report is ... methodological quality that may be relevant for the planned ...
... undergoing radiation treatments for head and neck cancer fare ... according to a study in the February issue of ... official journal of the American Society for Radiation Oncology ... smoking and head and neck cancers has long been ...
... have discovered a novel function of brain insulin, indicating that ... unrestrained lipolysis that initiates and worsens type 2 diabetes in ... Cell Metabolism . Led by Christoph Buettner, MD, ... and Bone Disease at Mount Sinai School of Medicine, the ...
... HealthDay Reporter , TUESDAY, Feb. 15 (HealthDay News) -- ... they,re first tested may not need to be screened annually ... study suggests. Dutch researchers presenting the findings at ... men with a PSA below 3.0 ng/ml were likely to ...
... Feb. 15 (HealthDay News) -- Men with prostate cancer may be ... baldness at the age of 20 than those without prostate cancer, ... hair in their 30s or 40s do not appear to face ... loss starts in their 20s do not face a higher risk ...
... more likely to be readmitted to the hospital after a ... pneumonia, according to a new study from Harvard School of ... rates were due to disparities related to both race and ... health and health care are well-documented in this country, but ...
Cached Medicine News:Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 2Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 3Health News:Smoking during radiation treatments reduces chance of overall survival 2Health News:Researchers find brain insulin plays critical role in the development of diabetes 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 3Health News:Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? 2Health News:Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? 3Health News:Study finds blacks more likely to be readmitted to hospitals after discharge 2
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: